Epigenetic Reprogramming in Relapse AML

NCT02412475 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped We opened a competing study with the TACL consortium

Conditions

Leukemia, Acute Myeloid

Interventions

DRUG: Decitabine
DRUG: Vorinostat
DRUG: Fludarabine
DRUG: Cytarabine
DRUG: Filgrastim
DRUG: Cytarabine
DRUG: Sorafenib

Sponsor

Michael Burke

Collaborators

[object Object]